What better way to celebrate 100 years of insulin than with the CEO of the company who is on the verge of giving us a vaccine for type 1 diabetes? 

We spoke to Ulf Hannelius in April and 3 days ago we saw the published results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical’s lead drug candidate Diamyd® (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Congratulations!

Guests who also joined us in this episode are Mark A. Atkinson, American Diabetes Association Eminent Scholar and Anders Ekholm, diabetes patient and parent, and Chairman of the Diabetes Association for Greater Stockholm.

Transcript

Keyword: insulin, diabetes, manufacturing, blood glucose level, pandemic, diabetic, recombinant insulin, biosynthetic insulin, type 1 diabetes.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Discovery Matters . Innehållet i podden är skapat av Discovery Matters och inte av, eller tillsammans med, Poddtoppen.